Rates of Long COVID in the U.S. Have Declined Since June of 2022
The share of people who say they have had long COVID has declined since the summer, according to a new…
Long COVID: What Do the Latest Data Show?
As of January 25, 2023, Centers for Disease Control and Prevention (CDC) data show that COVID cases, deaths, and hospitalizations…
Medicaid: What to Watch in 2023
As 2023 kicks off, a number of issues are at play that could affect coverage and financing under Medicaid, the…
Assessing the Role of Treaties, Conventions, Institutions, and Other International Agreements in the Global COVID-19 Response: Implications for the Future
Key Findings The COVID-19 pandemic has tested global health governance and international law in unprecedented ways, revealing weaknesses and gaps…
Most State Medicaid Programs Intend to Keep Pandemic-Era Expansions in Telehealth for Behavioral Health Services and Are Adopting Strategies to Address Workforce Shortages in Behavioral Health
Two new KFF analyses examine how state Medicaid programs have utilized telehealth to increase access to behavioral health care during…
Telehealth Delivery of Behavioral Health Care in Medicaid: Findings from a Survey of State Medicaid Programs
Telehealth can be an important component of facilitating access to care for Medicaid enrollees, particularly the nearly four in ten enrollees with…
Changes in Community Health Center Patients and Services During the COVID-19 Pandemic
Key Takeaways Community health centers are a national network of safety-net primary care providers serving low-income and medically underserved communities,…
KFF COVID-19 Vaccine Monitor: December 2022
Key Findings While most of the public continue to have confidence in the benefits of childhood vaccines for measles, mumps,…
COVID-19 Vaccines Could Cost Billions of Dollars More Each Year If the Federal Government Ends Its Bulk Purchasing Program
If the federal government runs out of money to purchase COVID-19 vaccines, the per-dose price likely would skyrocket and could…
How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization?
The federal government has spent more than $30 billion on COVID-19 vaccines, including the new bivalent boosters, incentivizing their development,…